Applikon Biotechnology Announces Important Breakthrough For The BioProcessing Market

Schiedam, The Netherlands - Applikon Biotechnology B.V., a leading manufacturer and supplier of high quality bioreactor systems, announces the launch of i-Control_XL, a significant breakthrough for the BioProcessing market. Applikon's products are used by the pharmaceutical, food, and chemical and process industries as well as research centres.

i-Control_XL is an easy-to-use platform and follows Applikon Biotechnology's 30 years' experience in bio-process control. Specifically designed for the bio-process industry, it offers industrial power, reliability and expandability using standard controllers (PLC) and distributed control systems (DCS).

As a result of i-Control_XL the scientist and engineering communities will enjoy a number of benefits including: intuitive navigation; a colour touch screen interface; options for bioreactor controls, pumps and sensors; the ability to use the same system to control autoclavable vessels, single-use bioreactors or SIP/CIP systems and impressively, the power to meet today's needs but with sufficient expandability to meet future needs.

Benefits specific to engineers include: a choice of controllers including Siemens, Allen Bradley or Delta V; fieldbus technology; the power and reliably of an industrial controller; a design adhering to the S88 guidelines and open system architecture.

Hans van den Berg, [manager M&B], at Applikon Biotechnology commented, "Bioprocess related issues such as high-throughput screening, scaling up, scaling down and PAT are no longer a trend, but a must in this arena. A Manufacturing Execution Systems (MES) involves managing engineering changes and tracing material for regulatory compliance, conforming to increasingly stringent quality standards, delivering on schedule despite shrinking lead times, and reducing costs. It is becoming increasingly important. Our i-Control_XL platform addresses these issues."

SOURCE: Applikon Biotechnology